Newsbenzinga
What's Going On With NextCure Stock Wednesday?
· Published
Article summary
NextCure ($NXTC) rises 2.1% premarket after presenting positive Phase 1 clinical data for ovarian cancer treatment SIM0505 at ASCO.
An excerpt from the original article.
Comments —
Loading comments…